BACKGROUND: In November 2001, the Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis and a high risk of death. The FDA required a study to evaluate the efficacy of DrotAA for adults who had s
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.All Scholarly Works
Document TypeArticle, Peer-reviewed
Citation InformationN Engl J Med. 2005 Sep 29;353(13):1332-41.